The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies

British Journal of Haematology

Volumn 151, Issue 2, 2010, Pages 167-178

  Buchner, Maike ^a   Brantner, Philipp ^a   Stickel, Natalie ^a   Prinz, Gabriele ^a   Burger, Meike ^a   Bär, Constance ^a   Dierks, Christine ^a   Pfeifer, Dietmar ^a   Ott, Ariane ^a   Mertelsmann, Roland ^a   Gribben, John G ^b   Veelken, Hendrik ^a   Zirlik, Katja ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

chemokines; chronic lymphocytic leukaemia; drug resistance; immunotherapy; stromal cells

Indexed keywords

ALEMTUZUMAB; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; IMMUNOLOGICAL ADJUVANT; PROTEIN KINASE B; PROTEIN MCL 1; RITUXIMAB;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL SYNAPSE; IMMUNOTHERAPY; MICROENVIRONMENT; MICROTUBULE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STROMA CELL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COMMUNICATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; NEOPLASM PROTEINS; RECEPTORS, CXCR4; STROMAL CELLS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 77957367164     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08316.x     Document Type: Article

References (61)

1. Awan, F.T., Kay, N.E., Davis, M.E., Wu, W., Geyer, S.M., Leung, N., Jelinek, D.F., Tschumper, R.C., Secreto, C.R., Lin, T.S., Grever, M.R., Shanafelt, T.D., Zent, C.S., Call, T.G., Heerema, N.A., Lozanski, G., Byrd, J.C. Lucas, D.M. (2009) Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood, 113, 535 537.
2. Balakrishnan, K., Burger, J.A., Wierda, W.G. Gandhi, V. (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood, 113, 149 153.
3. Biagi, E., Rousseau, R., Yvon, E., Schwartz, M., Dotti, G., Foster, A., Havlik-Cooper, D., Grilley, B., Gee, A., Baker, K., Carrum, G., Rice, L., Andreeff, M., Popat, U. Brenner, M. (2005) Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clinical Cancer Research, 11, 6916 6923.
4. Buchner, M., Fuchs, S., Prinz, G., Pfeifer, D., Bartholome, K., Burger, M., Chevalier, N., Vallat, L., Timmer, J., Gribben, J.G., Jumaa, H., Veelken, H., Dierks, C. Zirlik, K. (2009) Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Research, 69, 5424 5432.
5. Burger, J.A. Kipps, T.J. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107, 1761 1767.
6. Burger, J.A., Burger, M. Kipps, T.J. (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood, 94, 3658 3667.
7. Burger, M., Hartmann, T., Krome, M., Rawluk, J., Tamamura, H., Fujii, N., Kipps, T.J. Burger, J.A. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 106, 1824 1830.
8. Caligaris-Cappio, F. (2003) Role of the microenvironment in chronic lymphocytic leukaemia. British Journal of Haematology, 123, 380 388.
9. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754 758.
10. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
11. Chiorazzi, N., Rai, K.R. Ferrarini, M. (2005) Chronic lymphocytic leukemia. New England Journal of Medicine, 352, 804 815.
12. Chu, P., Wierda, W.G. Kipps, T.J. (2000) CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood, 95, 3853 3858.
13. Dalle, S., Thieblemont, C., Thomas, L. Dumontet, C. (2008) Monoclonal antibodies in clinical oncology. Anti-cancer agents in medicinal chemistry, 8, 523 532.
14. Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. Dalton, W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 1658 1667.
15. Dazzi, F., D'Andrea, E., Biasi, G., De Silvestro, G., Gaidano, G., Schena, M., Tison, T., Vianello, F., Girolami, A. Caligaris-Cappio, F. (1995) Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clinical Immunology and Immunopathology, 75, 26 32.
16. Edelmann, J., Klein-Hitpass, L., Carpinteiro, A., Fuhrer, A., Sellmann, L., Stilgenbauer, S., Duhrsen, U. Durig, J. (2008) Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leukemia Research, 32, 1565 1572.
17. Faderl, S., Coutre, S., Byrd, J.C., Dearden, C., Denes, A., Dyer, M.J., Gregory, S.A., Gribben, J.G., Hillmen, P., Keating, M., Rosen, S., Venugopal, P. Rai, K. (2005) The evolving role of alemtuzumab in management of patients with CLL. Leukemia, 19, 2147 2152.
18. Giannopoulos, K. Schmitt, M. (2006) Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leukaemia & Lymphoma, 47, 2028 2036.
19. Goping, I.S., Sawchuk, T., Rieger, A., Shostak, I. Bleackley, R.C. (2008) Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise. Blood, 111, 2142 2151.
20. Gorgun, G., Holderried, T.A., Zahrieh, D., Neuberg, D. Gribben, J.G. (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. Journal of Clinical Investigation, 115, 1797 1805.
21. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 1848 1854.
22. Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., Sadelain, M., Brentjens, R.J. Riviere, I. (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. Journal of Immunotherapy, 32, 169 180.
23. Hus, I., Rolinski, J., Tabarkiewicz, J., Wojas, K., Bojarska-Junak, A., Greiner, J., Giannopoulos, K., Dmoszynska, A. Schmitt, M. (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia, 19, 1621 1627.
24. Hus, I., Schmitt, M., Tabarkiewicz, J., Radej, S., Wojas, K., Bojarska-Junak, A., Schmitt, A., Giannopoulos, K., Dmoszynska, A. Rolinski, J. (2008) Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8 + T cells as well as CD4 + CD25 + FoxP3 + regulatory T cells toward an antileukemia response. Leukemia, 22, 1007 1017.
25. Hussain, S.R., Cheney, C.M., Johnson, A.J., Lin, T.S., Grever, M.R., Caligiuri, M.A., Lucas, D.M. Byrd, J.C. (2007) Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clinical Cancer Research, 13, 2144 2150.
26. Johnston, J.B., Paul, J.T., Neufeld, N.J., Haney, N., Kropp, D.M., Hu, X., Cheang, M. Gibson, S.B. (2004) Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leukaemia & Lymphoma, 45, 2017 2027.
27. Kater, A.P., Evers, L.M., Remmerswaal, E.B., Jaspers, A., Oosterwijk, M.F., van Lier, R.A., van Oers, M.H. Eldering, E. (2004a) CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. British Journal of Haematology, 127, 404 415.
28. Kater, A.P., Remmerswaal, E.B., Nolte, M.A., Eldering, E., van Oers, M.H. van Lier, R.A. (2004b) Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. British Journal of Haematology, 126, 512 516.
29. Kater, A.P., van Oers, M.H. Kipps, T.J. (2007) Cellular immune therapy for chronic lymphocytic leukemia. Blood, 110, 2811 2818.
30. Kato, K., Cantwell, M.J., Sharma, S. Kipps, T.J. (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. Journal of Clinical Investigation, 101, 1133 1141.
31. Katrinakis, G., Kyriakou, D., Papadaki, H., Kalokyri, I., Markidou, F. Eliopoulos, G.D. (1996) Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematologica, 96, 16 23.
32. Kay, N.E. Zarling, J.M. (1984) Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood, 63, 305 309.
33. Kay, N.E. Zarling, J. (1987) Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. American Journal of Hematology, 24, 161 167.
34. Khan, A., Greenman, J. Archibald, S.J. (2007) Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Current Medicinal Chemistry, 14, 2257 2277.
35. Khouri, I.F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A. Champlin, R. (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology, 16, 2817 2824.
36. Kitada, S., Zapata, J.M., Andreeff, M. Reed, J.C. (1999) Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 106, 995 1004.
37. Kurtova, A.V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M.P., Sivina, M., Wierda, W.G., Estrov, Z., Keating, M.J., Shehata, M., Jager, U., Gandhi, V., Kay, N.E., Plunkett, W. Burger, J.A. (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood, 114, 4441 4450.
38. Lefebvre, M.L., Krause, S.W., Salcedo, M. Nardin, A. (2006) Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. Journal of Immunotherapy, 29, 388 397.
39. Lim, C.K., Sun, L., Feng, Q., Law, P., Chua, W.T., Lim, S.N. Hwang, W.Y. (2008) Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. Journal of hematology & oncology, 1, 19.
40. Lim, S.H., Beers, S.A., French, R.R., Johnson, P.W., Glennie, M.J. Cragg, M.S. (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 95, 135 143.
41. Maurer, U., Charvet, C., Wagman, A.S., Dejardin, E. Green, D.R. (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Molecular Cell, 21, 749 760.
42. Mayr, C., Kofler, D.M., Buning, H., Bund, D., Hallek, M. Wendtner, C.M. (2005) Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood, 106, 3223 3226.
43. Nimmerjahn, F. Ravetch, J.V. (2006) Fcgamma receptors: old friends and new family members. Immunity, 24, 19 28.
44. Osterroth, F., Alkan, O., Mackensen, A., Lindemann, A., Fisch, P., Skerra, A. Veelken, H. (1999) Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. Journal of Immunological Methods, 229, 141 153.
45. Pepper, C., Lin, T.T., Pratt, G., Hewamana, S., Brennan, P., Hiller, L., Hills, R., Ward, R., Starczynski, J., Austen, B., Hooper, L., Stankovic, T. Fegan, C. (2008) Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, 112, 3807 3817.
46. Pfeifer, D., Pantic, M., Skatulla, I., Rawluk, J., Kreutz, C., Martens, U.M., Fisch, P., Timmer, J. Veelken, H. (2007) Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood, 109, 1202 1210.
47. Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgun, G., Le Dieu, R., Blum, W., Byrd, J.C. Gribben, J.G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation, 118, 2427 2437.
48. Rassenti, L.Z., Huynh, L., Toy, T.L., Chen, L., Keating, M.J., Gribben, J.G., Neuberg, D.S., Flinn, I.W., Rai, K.R., Byrd, J.C., Kay, N.E., Greaves, A., Weiss, A. Kipps, T.J. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. New England Journal of Medicine, 351, 893 901.
49. Schmidt, S.M., Schag, K., Muller, M.R., Weck, M.M., Appel, S., Kanz, L., Grunebach, F. Brossart, P. (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood, 102, 571 576.
50. Stanglmaier, M., Reis, S. Hallek, M. (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Annals of Hematology, 83, 634 645.
51. Stone, N.D., Dunaway, S.B., Flexner, C., Tierney, C., Calandra, G.B., Becker, S., Cao, Y.J., Wiggins, I.P., Conley, J., MacFarland, R.T., Park, J.G., Lalama, C., Snyder, S., Kallungal, B., Klingman, K.L. Hendrix, C.W. (2007) Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrobial Agents and Chemotherapy, 51, 2351 2358.
52. Tamamura, H., Omagari, A., Hiramatsu, K., Gotoh, K., Kanamoto, T., Xu, Y., Kodama, E., Matsuoka, M., Hattori, T., Yamamoto, N., Nakashima, H., Otaka, A. Fujii, N. (2001) Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorganic & Medicinal Chemistry Letters, 11, 1897 1902.
53. Uy, G.L., Rettig, M.P., McFarland, K.M., Hladnik, L.M., Kulkarni, S., Abboud, C.M., Cashen, A.F., Stockerl-Goldstein, K., Vij, R., Westervelt, P. DiPersio, J.F. (2008) Mobilization and chemosensitization of AML with the CXCR4 antagonist Plerixafor (AMD3100): a phase I/II study of AMD3100 + MEC in patients with relapsed or refractory disease. Blood, 112, 678a.
54. Voso, M.T., Pantel, G., Rutella, S., Weis, M., D'Alo, F., Urbano, R., Leone, G., Haas, R. Hohaus, S. (2002) Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica, 87, 918 925.
55. Weitzman, J., Betancur, M., Boissel, L., Rabinowitz, A.P., Klein, A. Klingemann, H. (2009) Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leukaemia & Lymphoma, 50, 1361 1368.
56. Wendt, M.K., Cooper, A.N. Dwinell, M.B. (2008) Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene, 27, 1461 1471.
57. Wolos, J.A. Davey, F.R. (1979) Depressed stimulation in the MLR by B lymphocytes on chronic lymphocytic leukemia: failure to demonstrate a suppressor cell. Clinical Immunology and Immunopathology, 14, 77 85.
58. Yoon, Y., Liang, Z., Zhang, X., Choe, M., Zhu, A., Cho, H.T., Shin, D.M., Goodman, M.M., Chen, Z.G. Shim, H. (2007) CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Research, 67, 7518 7524.
59. Zhou, P., Qian, L., Bieszczad, C.K., Noelle, R., Binder, M., Levy, N.B. Craig, R.W. (1998) Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood, 92, 3226 3239.
60. Zipfel, P.F. Skerka, C. (2009) Complement regulators and inhibitory proteins. Nature Reviews. Immunology, 9, 729 740.
61. Zirlik, K.M., Zahrieh, D., Neuberg, D. Gribben, J.G. (2006) Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood, 108, 3865 3870.